Horizon Space Acquisition II Corp

HSPT

Börsenwert 34 Mio. $

New York, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Horizon Space Acquisition II Corp. (the “Company” or “HSPT”) (NASDAQ: HSPT) today clarified the redemption process for (i) the extraordinary general meeting for its proposed business combination (the “Business Combination”) with SL BIO Ltd. (“SL Bio”), which will be held on February 12, 2026 (the “Business Combination Meeting”), and (ii) the extraordinary general meeting for its proposed amendments to HSPT's current amended and restated memorandum and articles of association, and the Investment Management Trust Agreement (collectively, the “Extension Proposals”), to extend the deadline to complete its initial business combination, which will be held on February 13, 2026 (the “Extension Meeting”).

New York, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Horizon Space Acquisition II Corp. (the “Company” or “HSPT”) (NASDAQ: HSPT) today announced that it postponed the extraordinary general meeting (the “Extraordinary Meeting”) originally scheduled at 9:00 a.m. Eastern Time, on February 3, 2026, to 9:00 a.m. Eastern Time, on February 12, 2026 (the “Postponement”) to allow the Company additional time to engage with its shareholders.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Horizon Space Acquisition II Corp. ("HSPT") (Nasdaq:HSPT), a publicly traded special purpose acquisition company, and SL Bio Ltd. ("SL Bio"), a clinical-stage biomedical company specialized in developing groundbreaking cellular and gene therapies for skin care and cancer recovery, today announced that they have entered into a definitive business combination agreement (the "Business Combination Agreement").